{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:40:32Z","timestamp":1774320032480,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe real\u2010world patient characteristics, prior treatment patterns, and associated healthcare resource utilization (HRU) and costs among patients with locally advanced\/metastatic urothelial carcinoma (la\/mUC) treated with enfortumab vedotin (EV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study used the United States (US) Centers for Medicare and Medicaid Services 100% Medicare claims data from 2015 to 2020. Included patients had a diagnosis of la\/mUC and received treatment with EV. The index date was the EV initiation date. Endpoints included HRU and costs 12\u2009months before the index date (baseline period) and treatment patterns before EV initiation. Results were summarized descriptively using means and standard deviations for continuous variables, and frequency counts and percentages for categorical variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 529 included patients, the mean age at the time of EV initiation was 76.5\u2009years. Most patients were White (88.1%) and male (77.1%). Common comorbidities were hypertension (85.1%), renal disease (65.2%), and peripheral vascular disease (42.5%). Platinum\u2010based chemotherapy was the most frequent therapy two lines before EV initiation (43.9%). The most frequent therapy in the line before EV initiation was PD\u20101\/L1 inhibitors (61.4%). The median duration of EV therapy was 4.1\u2009months. The mean all\u2010cause healthcare cost during the baseline period was $106\u2009258 per patient, and 86% had at least one outpatient visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This real\u2010world study demonstrated that most US patients with la\/mUC received platinum\u2010based chemotherapy or a PD\u20101\/L1 inhibitor prior to EV therapy from 2015 to 2020. HRU and costs 12\u2009months before EV initiation suggest a substantial burden in this population. Long\u2010term studies with more recent data are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.70023","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:30:48Z","timestamp":1741753848000},"page":"650-657","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced\/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real\u2010World Evidence Study"],"prefix":"10.1111","volume":"32","author":[{"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mucha","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Quicquaro","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Shih","sequence":"additional","affiliation":[{"name":"Pfizer  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xie","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Young","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Analysis Group  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Greatsinger","sequence":"additional","affiliation":[{"name":"Analysis Group  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Lax","sequence":"additional","affiliation":[{"name":"Analysis Group  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"\u201cSEER Cancer Stat Facts: Female Breast Cancer \u201d2021 https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"e_1_2_12_3_1","volume-title":"EAU Guidelines on Muscle\u2010Invasive and Metastatic Bladder Cancer","author":"Witjes J. A.","year":"2023"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2014.06.001"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12101745"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0041"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0072"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040277"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5534"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_2_12_14_1","unstructured":"\u201cFDA Grants Regular Approval to Enfortumab Vedotin\u2010EJFV for Locally Advanced or Metastatic Urothelial Cancer \u201d2021 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010regular\u2010approval\u2010enfortumab\u2010vedotin\u2010ejfv\u2010locally\u2010advanced\u2010or\u2010metastatic\u2010urothelial\u2010cancer."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01643"},{"key":"e_1_2_12_17_1","unstructured":"\u201cNCI Comorbidity Index Overview \u201d2023 https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1591424"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.001"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e16032"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.01.015"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.013"},{"key":"e_1_2_12_24_1","unstructured":"\u201cMedicare Coverage of Cancer Treatment Services \u201d(U.S. Department of Health and Human Services 2022)."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34057"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T03:03:18Z","timestamp":1749438198000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/iju.70023"],"URL":"https:\/\/doi.org\/10.1111\/iju.70023","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"2024-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}